JP2011510667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510667A5 JP2011510667A5 JP2010545343A JP2010545343A JP2011510667A5 JP 2011510667 A5 JP2011510667 A5 JP 2011510667A5 JP 2010545343 A JP2010545343 A JP 2010545343A JP 2010545343 A JP2010545343 A JP 2010545343A JP 2011510667 A5 JP2011510667 A5 JP 2011510667A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- polypeptide
- composition
- cartilage degeneration
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 210000000845 cartilage Anatomy 0.000 claims description 19
- 230000007850 degeneration Effects 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2631708P | 2008-02-05 | 2008-02-05 | |
| US8887608P | 2008-08-14 | 2008-08-14 | |
| PCT/CH2009/000045 WO2009097704A1 (en) | 2008-02-05 | 2009-02-05 | Antigen-binding polypeptides against cartilage degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011510667A JP2011510667A (ja) | 2011-04-07 |
| JP2011510667A5 true JP2011510667A5 (cg-RX-API-DMAC7.html) | 2013-01-24 |
Family
ID=40568129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545343A Pending JP2011510667A (ja) | 2008-02-05 | 2009-02-05 | 軟骨変性に対する抗原結合性ポリペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110002927A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2240515A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011510667A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101939335B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009212079B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0907485A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2712965A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL206720A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010136988A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009097704A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012040623A2 (en) | 2010-09-24 | 2012-03-29 | The Brigham And Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
| CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| EP3081234B1 (en) | 2013-12-13 | 2020-04-08 | Mercury Asset Management Co., Ltd. | Articular cartilage imaging composition |
| EP3978022A1 (en) * | 2016-05-06 | 2022-04-06 | The Brigham and Women's Hospital, Inc. | Binary self assembled gels for controlled delivery of encapsulated agents to cartilage |
| CA3113948A1 (en) | 2018-10-11 | 2020-04-16 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| ES2424042T3 (es) * | 2005-06-07 | 2013-09-26 | Esbatech - A Novartis Company Llc | Anticuerpos estables y solubles que inhiben TNF± |
| LT2046382T (lt) * | 2006-07-10 | 2016-12-12 | Esbatech, An Alcon Biomedical Research Unit Llc | Scfv antikūnai, pereinantys epitelio ir (arba) endotelio sluoksnius |
-
2009
- 2009-02-05 US US12/865,365 patent/US20110002927A1/en not_active Abandoned
- 2009-02-05 EP EP09707332A patent/EP2240515A1/en not_active Withdrawn
- 2009-02-05 CN CN200980104195.1A patent/CN101939335B/zh not_active Expired - Fee Related
- 2009-02-05 CA CA2712965A patent/CA2712965A1/en not_active Abandoned
- 2009-02-05 WO PCT/CH2009/000045 patent/WO2009097704A1/en not_active Ceased
- 2009-02-05 RU RU2010136988/10A patent/RU2010136988A/ru unknown
- 2009-02-05 BR BRPI0907485-6A patent/BRPI0907485A2/pt not_active Application Discontinuation
- 2009-02-05 AU AU2009212079A patent/AU2009212079B2/en not_active Ceased
- 2009-02-05 JP JP2010545343A patent/JP2011510667A/ja active Pending
-
2010
- 2010-06-30 IL IL206720A patent/IL206720A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12214048B2 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | |
| US20180118808A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP5600846B2 (ja) | キトサン基材高分子接合体及びその製造方法 | |
| KR102223224B1 (ko) | 이중으로 유도화된 키토산 나노입자 및 이의 제조 방법과 생체 내 유전자 도입을 위하여 이를 이용하는 방법 | |
| US11268099B2 (en) | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides | |
| JP7244582B2 (ja) | 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法 | |
| WO2016146261A1 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine | |
| JP2017008055A (ja) | 多価合成ナノキャリアワクチン | |
| JP2016533174A (ja) | ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用 | |
| JP2011510667A5 (cg-RX-API-DMAC7.html) | ||
| CN115175575A (zh) | 设计的细菌组合物及其用途 | |
| JP2020525540A (ja) | 免疫原性組成物 | |
| TWI612970B (zh) | 胜肽／β－１，３－葡聚糖複合體及其製造方法以及含有彼之醫藥組成物 | |
| US20240398918A1 (en) | Design of immunostimulatory protein-core spherical nucleic acids | |
| EP3821016A1 (en) | Protein-based micelles for the delivery of hydrophobic active compounds | |
| CN112839674B (zh) | 包含抗原肽-佐剂核苷酸缀合体的免疫诱导剂及包含其的药物组合物 | |
| JP2020505042A (ja) | リボソームｒｎａオリガミおよびそれを調製する方法 | |
| RU2010136988A (ru) | Антигенсвязывающие полипептиды против дегенерации хряща | |
| CN102088960A (zh) | 药物递送载质 | |
| CA2980329A1 (en) | Self assembling molecules for targeted drug delivery | |
| KR101579879B1 (ko) | ｓｉＲＮＡ 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물 | |
| Sun et al. | Nucleic acid nanostructure assisted immune modulation | |
| WO2018180819A1 (ja) | 免疫誘導剤及びそれを含む医薬組成物 | |
| He et al. | A nanobody-mediated drug system against largemouth bass virus delivered by bacterial nanocellulose in Micropterus salmoides | |
| Jetani et al. | Nucleic acid aptamers stabilize proteins against different types of stress conditions |